RhumbLine Advisers
PLSE icon

RhumbLine Advisers’s Pulse Biosciences PLSE Stock Holding History

RhumbLine Advisers’s Portfolio PLSE Stock Details PLSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$658K Buy
23,743
+841
+4% +$19.8K ﹤0.01% 2579
2026
Q1 		$494K Sell
22,902
-216
-0.9% -$3.99K ﹤0.01% 2618
2025
Q4 		$317K Sell
23,118
-2,950
-11% -$46K ﹤0.01% 2938
2025
Q3 		$461K Sell
26,068
-980
-4% -$15.5K ﹤0.01% 2754
2025
Q2 		$408K Sell
27,048
-327
-1% -$5.43K ﹤0.01% 2810
2025
Q1 		$440K Buy
27,375
+1,614
+6% +$30.1K ﹤0.01% 2653
2024
Q4 		$448K Buy
25,761
+9
+0% +$159 ﹤0.01% 2743
2024
Q3 		$452K Buy
25,752
+23
+0.1% +$392 ﹤0.01% 2764
2024
Q2 		$288K Buy
25,729
+1,608
+7% +$15.1K ﹤0.01% 3024
2024
Q1 		$210K Buy
24,121
+724
+3% +$6.66K ﹤0.01% 3152
2023
Q4 		$286K Buy
23,397
+5,660
+32% +$39.2K ﹤0.01% 3000
2023
Q3 		$71.5K Buy
17,737
+1,952
+12% +$12.1K ﹤0.01% 3564
2023
Q2 		$113K Buy
+15,785
New +$101K ﹤0.01% 3473
2022
Q2 		– Sell
-13,340
Closed -$65K – 3203
2022
Q1 		$65K Sell
13,340
-301
-2% -$2.46K ﹤0.01% 2953
2021
Q4 		$202K Sell
13,641
-252
-2% -$5.02K ﹤0.01% 2832
2021
Q3 		$300K Buy
13,893
+593
+4% +$12.8K ﹤0.01% 2766
2021
Q2 		$218K Sell
13,300
-1,087
-8% -$20.7K ﹤0.01% 2904
2021
Q1 		$341K Sell
14,387
-1,140
-7% -$34.1K ﹤0.01% 2655
2020
Q4 		$370K Buy
15,527
+975
+7% +$15.5K ﹤0.01% 2572
2020
Q3 		$172K Sell
14,552
-2,360
-14% -$25.4K ﹤0.01% 2733
2020
Q2 		$177K Buy
16,912
+2,515
+17% +$22.6K ﹤0.01% 2810
2020
Q1 		$103K Hold
14,397
– – ﹤0.01% 2772
2019
Q4 		$193K Buy
14,397
+68
+0.5% +$969 ﹤0.01% 2760
2019
Q3 		$221K Sell
14,329
-105
-0.7% -$1.36K ﹤0.01% 2713
2019
Q2 		$191K Buy
14,434
+875
+6% +$11.9K ﹤0.01% 2797
2019
Q1 		$239K Sell
13,559
-358
-3% -$5.62K ﹤0.01% 2668
2018
Q4 		$159K Buy
+13,917
New +$168K ﹤0.01% 2798
2017
Q3 		– Sell
-9,415
Closed -$325K – 2904
2017
Q2 		$325K Buy
+9,415
New +$259K ﹤0.01% 2517

Other funds holding PLSE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

RhumbLine Advisers's PLSE Position: Q2 2026 in Review

RhumbLine Advisers increased its Pulse Biosciences (PLSE) stake by 3.7% in Q2 2026, buying an estimated $19.8K and bringing the position to 23,743 shares worth $658K. The position accounts for ﹤0.01% of the portfolio, ranked #2579.

RhumbLine Advisers first reported a position in PLSE in Q2 2017 and has held it in 28 quarters since. 106 funds tracked by Wall St. Rank hold PLSE as of Q2 2026.

  • RhumbLine Advisers held 23,743 shares of Pulse Biosciences worth $658K as of Q2 2026.
  • RhumbLine Advisers bought 841 Pulse Biosciences shares in Q2 2026, an estimated $19.8K.
  • Pulse Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2579 holding.
  • RhumbLine Advisers first reported a position in Pulse Biosciences in Q2 2017 and has held it in 28 quarters since.
  • 106 funds tracked by Wall St. Rank held Pulse Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.